AstraZeneca's (AZN.US) rare disease drug trial did not meet expectations, causing a slight decrease in stock price.

Zhtng cijng APP huxn, slkng (AZN.US) zi yn yo w nsi l m dn kng zhndu AL din zhng yng bin xng de q lnghu shyn wi nng ddo ynchng hunzh shngcn q hu jinsho xn zi gun lin k zhdng csh de zhyo zhngdin, zh y jigu y cqin yji du zhng sn hunzh knng hubi de qdi xngchng luch. The Zhtng Financial APP learned that AstraZeneca (AZN.US)'s investigational drug ancerlamidumab did not meet the primary endpoint of extending patient survival or reducing heart-related hospitalizations in the Phase III clinical trial for AL amyloidosis. This result contrasts with the industry's earlier hopes for potential benefits for critically ill patients.